ライフサイエンスコーパス: nonalcoholic fatty liver disease

1 ld liver fibrosis in pediatric patients with nonalcoholic fatty liver disease.

2 s COP1 as a potential therapeutic target for nonalcoholic fatty liver disease.

3 and outcomes of alcoholic liver disease and nonalcoholic fatty liver disease.

4 pathogenesis of alcoholic liver disease and nonalcoholic fatty liver disease.

5 es mediate different aspects of both ALD and nonalcoholic fatty liver disease.

6 brosis severity in postmenopausal women with nonalcoholic fatty liver disease.

7 , while contrasting results were reported in nonalcoholic fatty liver disease.

8 eing considered as a target for treatment of nonalcoholic fatty liver disease.

9 s also been demonstrated in murine models of nonalcoholic fatty liver disease.

10 and hypertension, have been associated with nonalcoholic fatty liver disease.

11 ontent, mimicking the human condition termed nonalcoholic fatty liver disease.

12 lls in FASD Mthfr(+/-) mice, consistent with nonalcoholic fatty liver disease.

13 sis in a cohort of consecutive patients with nonalcoholic fatty liver disease.

14 related diseases such as type 2 diabetes and nonalcoholic fatty liver disease.

15 ysiological conditions and in the context of nonalcoholic fatty liver disease.

16 t ventricular (LV) function in subjects with nonalcoholic fatty liver disease.

17 therapeutic potential in obese patients with nonalcoholic fatty liver disease.

18 ere has been an increase in the incidence of nonalcoholic fatty liver disease.

19 h plasma triglyceride (TG) concentration and nonalcoholic fatty liver disease.

20 nto the mechanisms of metabolic syndrome and nonalcoholic fatty liver disease.

21 eficiency protects mice from obesity-related nonalcoholic fatty liver disease.

22 demia, impaired carbohydrate metabolism, and nonalcoholic fatty liver disease.

23 also typical hepatic manifestations such as nonalcoholic fatty liver disease.

24 ded new insights into metabolic syndrome and nonalcoholic fatty liver disease.

25 f obesity, augmenting insulin resistance and nonalcoholic fatty liver disease.

26 6.5 kg/m(2) ) with histologically confirmed nonalcoholic fatty liver disease.

27 f fetuin-A and diabetes can be attributed to nonalcoholic fatty liver disease.

28 but is now being overtaken by patients with nonalcoholic fatty liver disease.

29 reported high failure rates in patients with nonalcoholic fatty liver disease.

30 therapeutic applications in diseases such as nonalcoholic fatty liver disease.

31 ibrosis risk among postmenopausal women with nonalcoholic fatty liver disease.

32 r source of TG in the liver of patients with nonalcoholic fatty liver diseases.

33 d signaling as a new therapeutic approach to nonalcoholic fatty liver diseases.

34 In post-hoc analyses of patients with nonalcoholic fatty liver disease activity score >/=4 (n

35 steatohepatitis, 138 (47%) had reductions in nonalcoholic fatty liver disease activity score (NAS), a

36 evalence of fibrosis (P = 0.04) and a higher nonalcoholic fatty liver disease activity score (P = 0.0

37 ammation (r = 0.49, P = 2.35 x 10(-6) ), and nonalcoholic fatty liver disease activity score (r = 0.4

38 Although a decrease in the nonalcoholic fatty liver disease activity score could se

39 was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 his

40 leration in liver is not associated with the Nonalcoholic Fatty Liver Disease Activity Score or any o

41 an assays, steatosis graded according to the nonalcoholic fatty liver disease activity score, and nec

42 logistic regression, adjusting for baseline nonalcoholic fatty liver disease activity score.

43 Alcoholic and nonalcoholic fatty liver disease (ALD and NAFLD) are the

44 ausal women with (1) histologic diagnosis of nonalcoholic fatty liver disease and (2) self-reported i

45 tion was undertaken in 17 men and women with nonalcoholic fatty liver disease and 15 body mass index

46 Diet-related health issues such as nonalcoholic fatty liver disease and cardiovascular diso

47 s in first-degree relatives of patients with nonalcoholic fatty liver disease and cirrhosis (NAFLD-ci

48 associated with liver disease, particularly nonalcoholic fatty liver disease and cirrhosis, and this

49 In biopsy-characterized cases of nonalcoholic fatty liver disease and controls, we assess

50 -fat diet, the KO mice developed features of nonalcoholic fatty liver disease and had increased level

51 s in the United States are estimated to have nonalcoholic fatty liver disease and its potential morbi

52 Nonalcoholic fatty liver disease and its subtype nonalco

53 iant rs58542926 is a genetic risk factor for nonalcoholic fatty liver disease and progression to fibr

54 useful for understanding the pathogenesis of nonalcoholic fatty liver disease and type 2 diabetes, as

55 er-related mortality in patients with NAFLD (nonalcoholic fatty liver disease) and AFLD (alcoholic fa

56 h poorly controlled type 2 diabetes and with nonalcoholic fatty liver disease, and a common variant o

57 ated with obesity, type 2 diabetes mellitus, nonalcoholic fatty liver disease, and cardiovascular dis

58 Outcomes of interest were any liver disease, nonalcoholic fatty liver disease, and cirrhosis (any eti

59 cal liver damage in alcoholic liver disease, nonalcoholic fatty liver disease, and hepatitis C, but n

60 cyte death is associated with progression of nonalcoholic fatty liver disease, and inhibition of apop

61 s, insulin resistance and diabetes mellitus, nonalcoholic fatty liver disease, and obesity.

62 n obese and diabetic murine models and human nonalcoholic fatty liver disease, and thus it correlates

63 yte-specific ablation of Tnfaip3 exacerbated nonalcoholic fatty liver disease- and NASH-related pheno

64 Both alcoholic liver disease (ALD) and nonalcoholic fatty liver disease are characterized by ma

65 epatic steatosis, an important precursor for nonalcoholic fatty liver disease, are undefined.

66 kely increase given the aging population and nonalcoholic fatty liver disease as a leading indication

67 the TM6SF2 gene is associated with pediatric nonalcoholic fatty liver disease but may confer protecti

68 nfers resistance to diet-induced obesity and nonalcoholic fatty liver disease by reducing food intake

69 abetes (T2D) and obesity are associated with nonalcoholic fatty liver disease, cardiomyopathy, and ca

70 expression was observed in a subset of human nonalcoholic fatty liver disease cases.

71 ase, polyps, cancer, liver disease including nonalcoholic fatty liver disease, cirrhosis, hepatocellu

72 Twenty-six of the 120 subjects (21.7%) had nonalcoholic fatty liver disease (defined as MRI-PDFF >/

73 pe 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, a

74 atio index (APRI), fibrosis-4 (FIB-4) score, nonalcoholic fatty liver disease fibrosis score (NFS), a

75 In nonalcoholic fatty liver disease, Gal-9 is involved indi

76 Nonalcoholic fatty liver disease has emerged as a novel

77 (obesity, metabolic syndrome, diabetes, and nonalcoholic fatty liver disease) have been associated w

78 In nonalcoholic fatty liver disease, hepatic gene expressio

79 lase is a potential therapeutic approach for nonalcoholic fatty liver disease, hepatic insulin resist

80 In obese, insulin-resistant patients with nonalcoholic fatty liver disease, hepatic mIndy expressi

81 (M+) and extra large (XL+), in patients with nonalcoholic fatty liver disease in a multicenter settin

82 diabetes, extreme hypertriglyceridemia, and nonalcoholic fatty liver disease in both families.

83 cerides (IHTGs), and is the primary cause of nonalcoholic fatty liver disease in obese individuals.

84 tocyte Shp1 as a potential novel mediator of nonalcoholic fatty liver diseases in obesity.

85 Nonalcoholic fatty liver disease is a common consequence

86 Nonalcoholic fatty liver disease is a heterogeneous diso

87 Nonalcoholic fatty liver disease is associated with hepa

88 Nonalcoholic fatty liver disease is associated with meta

89 Nonalcoholic fatty liver disease is becoming the most co

90 Nonalcoholic fatty liver disease is increasing in preval

91 Nonalcoholic fatty liver disease is now acknowledged as

92 Nonalcoholic fatty liver disease is one of the most prev

93 Nonalcoholic fatty liver disease is seen as the hepatic

94 The cause of nonalcoholic fatty liver disease is the aberrant accumul

95 Nonalcoholic fatty liver disease is the most common caus

96 Nonalcoholic fatty liver disease is the most common live

97 hird leading cause of death in patients with nonalcoholic fatty liver disease, is predicted to become

98 in, glucose intolerance, insulin resistance, nonalcoholic fatty liver disease measures; and serum lev

99 tegorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according to th

100 42926 C/T) variant on blood lipid traits and nonalcoholic fatty liver disease (NAFLD) across differen

101 ivers were assessed histologically using the nonalcoholic fatty liver disease (NAFLD) activity score

102 rth America, included subjects with NASH and nonalcoholic fatty liver disease (NAFLD) activity scores

103 Nonalcoholic fatty liver disease (NAFLD) alters drug res

104 Little is known about the prevalence of nonalcoholic fatty liver disease (NAFLD) among severely

105 Nonalcoholic fatty liver disease (NAFLD) and alcoholic l

106 essment of disease activity in patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic l

107 ves many obesity-related diseases, including nonalcoholic fatty liver disease (NAFLD) and diabetes, a

108 167Lys) variant in genetic susceptibility to nonalcoholic fatty liver disease (NAFLD) and disease sev

109 Nonalcoholic fatty liver disease (NAFLD) and heart failu

110 The incidence of nonalcoholic fatty liver disease (NAFLD) and hyperlipide

111 of saturated fat is a likely contributor to nonalcoholic fatty liver disease (NAFLD) and insulin res

112 lay an important role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and its progres

113 plore the role of liver aminotransferases in nonalcoholic fatty liver disease (NAFLD) and MetS.

114 L27RA), resembling the phenotype observed in nonalcoholic fatty liver disease (NAFLD) and nonalcoholi

115 Nonalcoholic fatty liver disease (NAFLD) and resulting n

116 The early stages of nonalcoholic fatty liver disease (NAFLD) are characteriz

117 Alcoholic fatty liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are common caus

118 Obstructive sleep apnea syndrome (OSAS) and nonalcoholic fatty liver disease (NAFLD) are frequently

119 rowing because obesity, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD) are replacing v

120 Patients with nonalcoholic fatty liver disease (NAFLD) are reported to

121 Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are significant

122 Inadvertent inclusion of subjects with nonalcoholic fatty liver disease (NAFLD) as controls can

123 epatic triglyceride (IHTG) content to define nonalcoholic fatty liver disease (NAFLD) by proton magne

124 Nonalcoholic fatty liver disease (NAFLD) can progress fr

125 Nonalcoholic fatty liver disease (NAFLD) comprises a spe

126 Nonalcoholic fatty liver disease (NAFLD) contributes to

127 ding on the liver transcriptome during early nonalcoholic fatty liver disease (NAFLD) development.

128 Nonalcoholic fatty liver disease (NAFLD) encompasses a r

129 Nonalcoholic fatty liver disease (NAFLD) encompasses a s

130 aging technique, are accurate for diagnosing nonalcoholic fatty liver disease (NAFLD) fibrosis.

131 Nonalcoholic fatty liver disease (NAFLD) has become a ma

132 Nonalcoholic fatty liver disease (NAFLD) has become high

133 Among these sequelae, nonalcoholic fatty liver disease (NAFLD) has become the

134 No treatment for nonalcoholic fatty liver disease (NAFLD) has been approv

135 An association between periodontitis and nonalcoholic fatty liver disease (NAFLD) has been report

136 The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased w

137 obesity, the IM composition of patients with nonalcoholic fatty liver disease (NAFLD) has not been we

138 The majority of patients with nonalcoholic fatty liver disease (NAFLD) have "simple st

139 Pediatric nonalcoholic fatty liver disease (NAFLD) histology demon

140 (PPP1R3B) that were strongly associated with nonalcoholic fatty liver disease (NAFLD) in adults of Eu

141 ients with type 2 diabetes (T2D) and reduces nonalcoholic fatty liver disease (NAFLD) in animal model

142 Nonalcoholic fatty liver disease (NAFLD) in non-obese pa

143 An independent role of nonalcoholic fatty liver disease (NAFLD) in the developm

144 V) as an independent biomarker of CT-defined nonalcoholic fatty liver disease (NAFLD) in the offsprin

145 igh-fructose corn syrup (HFCS), and rates of nonalcoholic fatty liver disease (NAFLD) in the United S

146 The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty

147 The prevalence of nonalcoholic fatty liver disease (NAFLD) increases with

148 o analyzed the effects of obesity-associated nonalcoholic fatty liver disease (NAFLD) independent of

149 to segregate patients with well-compensated nonalcoholic fatty liver disease (NAFLD) into subpopulat

150 Nonalcoholic fatty liver disease (NAFLD) is a burgeoning

151 Nonalcoholic fatty liver disease (NAFLD) is a common liv

152 Nonalcoholic fatty liver disease (NAFLD) is a common pro

153 Nonalcoholic fatty liver disease (NAFLD) is a complex ch

154 BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is a consequenc

155 Nonalcoholic fatty liver disease (NAFLD) is a leading ca

156 Nonalcoholic fatty liver disease (NAFLD) is a leading ca

157 Nonalcoholic fatty liver disease (NAFLD) is a major caus

158 Nonalcoholic fatty liver disease (NAFLD) is a major caus

159 Importance: Nonalcoholic fatty liver disease (NAFLD) is a major chro

160 Nonalcoholic fatty liver disease (NAFLD) is a major fact

161 Nonalcoholic fatty liver disease (NAFLD) is a major worl

162 Nonalcoholic fatty liver disease (NAFLD) is a rapidly em

163 Nonalcoholic fatty liver disease (NAFLD) is a risk facto

164 Nonalcoholic fatty liver disease (NAFLD) is a significan

165 There is evidence that nonalcoholic fatty liver disease (NAFLD) is affected by

166 ection of liver fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) is an important

167 Nonalcoholic fatty liver disease (NAFLD) is an increasin

168 Nonalcoholic fatty liver disease (NAFLD) is an obesity-r

169 Nonalcoholic fatty liver disease (NAFLD) is associated w

170 Nonalcoholic fatty liver disease (NAFLD) is associated w

171 BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is associated w

172 Nonalcoholic fatty liver disease (NAFLD) is characterize

173 Nonalcoholic fatty liver disease (NAFLD) is characterize

174 Although nonalcoholic fatty liver disease (NAFLD) is closely link

175 oderate alcohol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet

176 Although nonalcoholic fatty liver disease (NAFLD) is conventional

177 Nonalcoholic fatty liver disease (NAFLD) is highly preva

178 Nonalcoholic fatty liver disease (NAFLD) is increasingly

179 e clinical and public health significance of nonalcoholic fatty liver disease (NAFLD) is not well est

180 ver, the role of FOXOs in the development of nonalcoholic fatty liver disease (NAFLD) is not well und

181 Nonalcoholic fatty liver disease (NAFLD) is now the most

182 With no approved pharmacological treatment, nonalcoholic fatty liver disease (NAFLD) is now the most

183 Nonalcoholic fatty liver disease (NAFLD) is one of the m

184 Nonalcoholic fatty liver disease (NAFLD) is one of the m

185 Nonalcoholic fatty liver disease (NAFLD) is the hepatic

186 Nonalcoholic fatty liver disease (NAFLD) is the most com

187 Nonalcoholic fatty liver disease (NAFLD) is the most com

188 Nonalcoholic fatty liver disease (NAFLD) is the most com

189 Nonalcoholic fatty liver disease (NAFLD) is the most com

190 Nonalcoholic fatty liver disease (NAFLD) is the most com

191 Nonalcoholic fatty liver disease (NAFLD) is the most com

192 Nonalcoholic fatty liver disease (NAFLD) is the most com

193 Nonalcoholic fatty liver disease (NAFLD) is the most com

194 Nonalcoholic fatty liver disease (NAFLD) is the most com

195 Nonalcoholic fatty liver disease (NAFLD) is the most com

196 Nonalcoholic fatty liver disease (NAFLD) is the most com

197 Nonalcoholic fatty liver disease (NAFLD) is the most pre

198 Nonalcoholic fatty liver disease (NAFLD) is widespread i

199 e is ongoing debate on whether screening for nonalcoholic fatty liver disease (NAFLD) is worthwhile i

200 Nonalcoholic fatty liver disease (NAFLD) may increase th

201 Nonalcoholic fatty liver disease (NAFLD) may lead to hep

202 The origins of nonalcoholic fatty liver disease (NAFLD) may lie in earl

203 termine the influence of steatotic drugs and nonalcoholic fatty liver disease (NAFLD) on SHP expressi

204 model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is la

205 n developed in chronic hepatitis C (CHC) and nonalcoholic fatty liver disease (NAFLD) patients.

206 inations and forms (alive or lyophilized) in nonalcoholic fatty liver disease (NAFLD) prevention.

207 c steatosis among HIV-infected patients with nonalcoholic fatty liver disease (NAFLD) receiving EFV p

208 Nonalcoholic fatty liver disease (NAFLD) represents an e

209 Nonalcoholic fatty liver disease (NAFLD) represents the

210 Nonalcoholic fatty liver disease (NAFLD) spectrum disord

211 Nonalcoholic fatty liver disease (NAFLD) was the most co

212 ies have identified a cholestatic variant of nonalcoholic fatty liver disease (NAFLD) with portal inf

213 Nonalcoholic fatty liver disease (NAFLD), a common prelu

214 pathological polyploidization takes place in nonalcoholic fatty liver disease (NAFLD), a widespread h

215 e and insulin sensitivity are widely used in nonalcoholic fatty liver disease (NAFLD), although they

216 onsumption is associated with lower risk for nonalcoholic fatty liver disease (NAFLD), an obesity-rel

217 plays a relevant role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), and both risky

218 en suggested to be a key factor that induces nonalcoholic fatty liver disease (NAFLD), but the eviden

219 otein 3 (PNPLA3) is strongly associated with nonalcoholic fatty liver disease (NAFLD), but the mechan

220 ve been shown to contribute significantly to nonalcoholic fatty liver disease (NAFLD), data are prese

221 Nonalcoholic fatty liver disease (NAFLD), hepatic insuli

222 Most researchers focused on nonalcoholic fatty liver disease (NAFLD), in which incre

223 s (NASH), a clinically aggressive variant of nonalcoholic fatty liver disease (NAFLD), is becoming an

224 During nonalcoholic fatty liver disease (NAFLD), mitochondria a

225 PPARgamma activation may induce obesity and nonalcoholic fatty liver disease (NAFLD), one of the mos

226 atohepatitis (NASH), a more advanced form of nonalcoholic fatty liver disease (NAFLD), predisposes pa

227 Nonalcoholic fatty liver disease (NAFLD), the accumulati

228 Nonalcoholic fatty liver disease (NAFLD), the most commo

229 Despite the high prevalence of nonalcoholic fatty liver disease (NAFLD), therapeutic op

230 ns are considered the first-line therapy for nonalcoholic fatty liver disease (NAFLD), which is extre

231 Type 1 diabetes has been recently linked to nonalcoholic fatty liver disease (NAFLD), which is known

232 2 p.E167K, and GCKR p.P446L) associated with nonalcoholic fatty liver disease (NAFLD).

233 n of LRH-1 SUMOylation to the development of nonalcoholic fatty liver disease (NAFLD).

234 s of fibrosis and steatosis in patients with nonalcoholic fatty liver disease (NAFLD).

235 ave emphasized the role of gut microbiota in nonalcoholic fatty liver disease (NAFLD).

236 atic steatosis in different murine models of nonalcoholic fatty liver disease (NAFLD).

237 s of fibrosis and steatosis in patients with nonalcoholic fatty liver disease (NAFLD).

238 decreased in obesity, a key risk factor for nonalcoholic fatty liver disease (NAFLD).

239 oses to the full spectrum of liver damage in nonalcoholic fatty liver disease (NAFLD).

240 fibrosis, a major determinant of outcome in nonalcoholic fatty liver disease (NAFLD).

241 ALT]) are usually increased in patients with nonalcoholic fatty liver disease (NAFLD).

242 ebotomy has been proposed as a treatment for nonalcoholic fatty liver disease (NAFLD).

243 58 per 100,000 enrollees), driven by HCV and nonalcoholic fatty liver disease (NAFLD).

244 C) is increasingly reported in patients with nonalcoholic fatty liver disease (NAFLD).

245 specimens allows for grading and staging of nonalcoholic fatty liver disease (NAFLD).

246 nsulin resistance are highly associated with nonalcoholic fatty liver disease (NAFLD).

247 ted disorders, including type 2 diabetes and nonalcoholic fatty liver disease (NAFLD).

248 have been associated with the occurrence of nonalcoholic fatty liver disease (NAFLD).

249 ates with advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).

250 of de novo lipogenesis in the development of nonalcoholic fatty liver disease (NAFLD).

251 mic of obesity and insulin resistance favors nonalcoholic fatty liver disease (NAFLD).

252 y play a crucial role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).

253 f nonalcoholic steatohepatitis (NASH) within nonalcoholic fatty liver disease (NAFLD).

254 er plays a causal role in the progression of nonalcoholic fatty liver disease (NAFLD).

255 t may re-program liver for increased risk of nonalcoholic fatty liver disease (NAFLD).

256 e leading cause of death among patients with nonalcoholic fatty liver disease (NAFLD).

257 the most important predictor of mortality in nonalcoholic fatty liver disease (NAFLD).

258 cohort of adult patients suspected of having nonalcoholic fatty liver disease (NAFLD).

259 of type 2 diabetes (T2D), and improvement of nonalcoholic fatty liver disease (NAFLD).

260 ls in the serum, is strongly associated with nonalcoholic fatty liver disease (NAFLD).

261 restimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD).

262 Despite this, little evidence of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic st

263 in AAs (BCAAs), are often found increased in nonalcoholic fatty liver disease (NAFLD); however, if th

264 fructose and other sugars has been linked to nonalcoholic fatty liver disease (NAFLD); however, the s

265 ant proportion of the phenotypic variance of nonalcoholic fatty liver disease (NAFLD); however, very

266 The histological spectrum of nonalcoholic fatty liver diseases (NAFLD) ranges from he

267 s), due to chronic hepatitis C; hepatitis B; nonalcoholic fatty liver diseases (NAFLD); and alcoholic

268 e this, we enrolled 190 patients (32 without nonalcoholic fatty liver disease [NAFLD], 36 with simple

269 prevalence of obesity-induced liver disease (nonalcoholic fatty liver disease; NAFLD) is rising.

270 ffects of bariatric surgery in patients with nonalcoholic fatty liver disease (NASH) are not well est

271 evelop from metabolic liver disease, such as nonalcoholic fatty liver disease (NASH).

272 nd antibiotic-associated diarrhea, diabetes, nonalcoholic fatty liver disease, necrotizing enterocoli

273 y senescence were evaluated in patients with nonalcoholic fatty liver disease, nonalcoholic steatohep

274 ng of HIV infection include viral hepatitis, nonalcoholic fatty liver disease/nonalcoholic steatohepa

275 bolic syndrome, impaired glucose metabolism, nonalcoholic fatty liver disease, obstructive sleep apno

276 nd increases in percentages of patients with nonalcoholic fatty liver disease or ALD.

277 wth factor (FGF)21 increase in patients with nonalcoholic fatty liver disease or nonalcoholic steatoh

278 s for which obesity is the direct cause (eg, nonalcoholic fatty liver disease) or is a significant ri

279 CC, proportions of those with HCV infection, nonalcoholic fatty liver disease, or ALD did not change

280 ding cause of fibrosis (viral hepatitis C vs nonalcoholic fatty liver disease, P = .025), inflammatio

281 soriasis may be more severe in patients with nonalcoholic fatty liver disease, particularly in those

282 al of 51 NAFL patients, 30 NASH patients, 31 nonalcoholic fatty liver disease patients (without histo

283 e is associated with severity of fibrosis in nonalcoholic fatty liver disease patients of European an

284 ZB exerted no toxicity in liver tissues from nonalcoholic fatty liver disease patients.

285 The incidence of nonalcoholic fatty liver disease-related hepatocellular

286 ferase expression in a diet-induced model of nonalcoholic fatty liver disease reveals onset of hepati

287 ar after surgery (IQR, 2.5%-21.3%); the mean nonalcoholic fatty liver disease score was reduced from

288 upt intestinal homeostasis and contribute to nonalcoholic fatty liver disease, steatohepatitis, alcoh

289 Nonalcoholic fatty liver disease (steatosis) is the most

290 ic steatohepatitis subtype within those with nonalcoholic fatty liver disease still requires liver bi

291 In nonalcoholic fatty liver disease, the influence of sever

292 In patients with nonalcoholic fatty liver disease, the presence of severe

293 ease, type 2 diabetes mellitus, obesity, and nonalcoholic fatty liver disease through modulation of m

294 e (rs738409 C>G) is strongly associated with nonalcoholic fatty liver disease; to our knowledge, no d

295 Nonalcoholic fatty liver disease was diagnosed in 68 pat

296 Incident nonalcoholic fatty liver disease was highest in patients

297 In patients with nonalcoholic fatty liver disease, we found no correlatio

298 induced intestinal dysbiosis is a driver for nonalcoholic fatty liver disease, we hypothesized that C

299 elevated fasting plasma glucose levels, and nonalcoholic fatty liver disease were also associated wi

300 10 mg/dL, RR = 1.68, 95% CI: 1.10-3.87), and nonalcoholic fatty liver disease (yes versus no, RR = 1.